Publications

BibTex format

@article{Fortner:2017:10.1186/s12916-017-0786-8,
author = {Fortner, RT and Sarink, D and Schock, H and Johnson, T and Tjonneland, A and Olsen, A and Overvad, K and Affret, A and His, M and Boutron-Ruault, M and Boeing, H and Trichopoulou, A and Naska, A and Orfanos, P and Palli, D and Sieri, S and Mattiello, A and Tumino, R and Ricceri, F and Bueno-de-Mequita, H and Peeters, PHM and van, Gils CH and Weiderpass, E and Lund, E and Ramon, Quiros J and Agudo, A and Sanchez, M and Chirlaque, M and Ardanaz, E and Dorronsoro, M and Key, T and Khaw, K and Rinaldi, S and Dossus, L and Gunter, M and Merritt, MA and Riboli, E and Kaaks, R},
doi = {10.1186/s12916-017-0786-8},
journal = {BMC Medicine},
title = {Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.},
url = {http://dx.doi.org/10.1186/s12916-017-0786-8},
volume = {15},
year = {2017}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundCirculating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study.MethodsA case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER–, n = 386), matched 1:1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression.ResultsThe associations between OPG and ER+ and ER– breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER– breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24–3.02]; p trend = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER– disease did not differ by menopausal status at blood collection (p het = 0.97), and we observed no heterogeneity by HT use at blood collection (p het ≥ 0.43) or age at breast cancer diagnosis (p het ≥ 0.30).ConclusionsThis study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER– breast cancer.
AU  - Fortner,RT
AU  - Sarink,D
AU  - Schock,H
AU  - Johnson,T
AU  - Tjonneland,A
AU  - Olsen,A
AU  - Overvad,K
AU  - Affret,A
AU  - His,M
AU  - Boutron-Ruault,M
AU  - Boeing,H
AU  - Trichopoulou,A
AU  - Naska,A
AU  - Orfanos,P
AU  - Palli,D
AU  - Sieri,S
AU  - Mattiello,A
AU  - Tumino,R
AU  - Ricceri,F
AU  - Bueno-de-Mequita,H
AU  - Peeters,PHM
AU  - van,Gils CH
AU  - Weiderpass,E
AU  - Lund,E
AU  - Ramon,Quiros J
AU  - Agudo,A
AU  - Sanchez,M
AU  - Chirlaque,M
AU  - Ardanaz,E
AU  - Dorronsoro,M
AU  - Key,T
AU  - Khaw,K
AU  - Rinaldi,S
AU  - Dossus,L
AU  - Gunter,M
AU  - Merritt,MA
AU  - Riboli,E
AU  - Kaaks,R
DO  - 10.1186/s12916-017-0786-8
PY  - 2017///
SN  - 1741-7015
TI  - Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.
T2  - BMC Medicine
UR  - http://dx.doi.org/10.1186/s12916-017-0786-8
UR  - http://hdl.handle.net/10044/1/44512
VL  - 15
ER  -

Download

ProfessorElioRiboli

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)